Understanding how certain kinases contribute to the death of retinal ganglion cells in glaucoma
Elucidating the Role of the Thousand and One Kinases in Retinal Ganglion Cell Death
This study is looking at how certain proteins in the eye might contribute to the death of important nerve cells in glaucoma, with the hope of finding new ways to help protect your vision beyond just lowering eye pressure.
Quick facts
| Grant type | Fellowship grant |
|---|---|
| Study type | NIH-funded research |
| Funding institution | University of California, San Diego NIH-funded |
| Lab location | 1 site (La Jolla, United States) |
| Project ID | NIH-11166108 on NIH RePORTER |
What this research studies
This research investigates the role of specific kinases in the death of retinal ganglion cells (RGCs) caused by glaucoma, a condition that leads to vision loss. The study aims to identify how these kinases, particularly TAOK1 and TAOK2, regulate cell death following axon injury. By using advanced genomic screening techniques, the researchers will explore the signaling pathways involved in RGC survival and death. This could lead to new therapeutic strategies that go beyond current treatments focused solely on lowering eye pressure.
Who could benefit from this research
Good fit: Ideal candidates for this research are individuals diagnosed with glaucoma who are experiencing vision loss.
Not a fit: Patients with glaucoma who have already lost significant vision or those with other unrelated eye conditions may not benefit from this research.
Why it matters
Potential benefit: If successful, this research could lead to new treatments that protect retinal ganglion cells and preserve vision in patients with glaucoma.
How similar studies have performed: Previous research has shown promise in targeting similar pathways for neuroprotection in other conditions, suggesting potential success for this approach.
Where this research is happening
La Jolla, United States
- University of California, San Diego — La Jolla, United States (Active)
Researchers
- Principal investigator: Chapman, Sean — University of California, San Diego
- Study coordinator: Chapman, Sean
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page below.